CYT
Income statement / Annual
Last year (2022), Cyteir Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Cyteir Therapeutics, Inc.'s net income was -$43.95 M.
See Cyteir Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$8,000.00
|
| Cost of Revenue |
$1.38 M |
$479,000.00 |
$351,000.00 |
$12,689.00 |
| Gross Profit |
-$1.38 M |
-$479,000.00 |
-$351,000.00 |
-$4,689.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
-0.59 |
| Research and Development
Expenses |
$34.62 M
|
$30.96 M
|
$16.77 M
|
$12.77 M
|
| General & Administrative
Expenses |
$13.55 M
|
$11.30 M
|
$4.18 M
|
$3.35 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.55 M
|
$11.30 M
|
$4.18 M
|
$3.35 M
|
| Other Expenses |
$2.11 M |
$133,000.00 |
$120,000.00 |
-$8,000.00 |
| Operating Expenses |
$48.17 M |
$42.26 M |
$20.94 M |
$16.11 M |
| Cost And Expenses |
$48.17 M |
$42.26 M |
$20.94 M |
$16.11 M |
| Interest Income |
$0.00 |
$133,000.00 |
$120,000.00 |
$246,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$668,000.00
|
$479,000.00
|
$351,000.00
|
$215,000.00
|
| EBITDA |
-$47.50 M
|
-$41.78 M
|
-$20.59 M
|
-$15.89 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-1986.25 |
| Operating Income Ratio
|
0
|
0
|
0
|
-2013.13
|
| Total Other
Income/Expenses Net |
$2.11 M
|
$133,000.00
|
$120,000.00
|
$1.06 M
|
| Income Before Tax |
-$46.06 M |
-$42.13 M |
-$20.82 M |
-$15.04 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-1880.5
|
| Income Tax Expense |
-$2.11 M |
-$479,000.00 |
$0.00 |
$0.00 |
| Net Income |
-$43.95 M |
-$41.65 M |
-$20.82 M |
-$15.04 M |
| Net Income Ratio |
0 |
0 |
0 |
-1880.5 |
| EPS |
-1.25 |
-2.14 |
-0.87 |
-0.77 |
| EPS Diluted |
-1.25 |
-2.14 |
-0.87 |
-0.77 |
| Weighted Average Shares
Out |
$35.27 M
|
$19.50 M
|
$23.89 M
|
$19.43 M
|
| Weighted Average Shares
Out Diluted |
$35.27 M
|
$19.50 M
|
$23.89 M
|
$19.43 M
|
| Link |
|
|
|
|
